New surgically developed devices are driving the Glaucoma market, according to Kristen Ingenito.
Across the globe, glaucomax's gross revenue is estimated to hit $6.1 billion with pharmaceuticals capturing 80% of the pie. Pharma shares of that segment are divided among fixed-combination drugs at 29%; branded and generic prostaglandins at 14%; beta-blockers at 7%; carbonic anhydrase inhibitors and alpha agonists (rare in the US) at 5%; and miscellaneous drugs at 5%.
I am seeing great openness and willingness to accept new technologies in the glaucoma space. This is extremely exciting considering all of the new advances coming in this field. A few leading experts cited by Ms. Ingenito welcome the expansion of minimally-invasive procedures (MIGS), while others commented that while some MIGs are useful, they do not hold the same exchange rate as some other devices or pharmaceuticals.
Anne Lienosa, noted that there are up to 132 million people with Glaucoma currently, with the number anticipated to rise in 169 million by 2026.
Assure and Integria Healthcare provide their nations' healthcare system with steps maximizing competition and relevance of findings for the research and content development.
You must be logged in to post a comment.